| Enrolling By Invitation | Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A o NCT06285071 | Novo Nordisk A/S | — |
| Completed | A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese NCT05365217 | Novo Nordisk A/S | Phase 3 |
| Active Not Recruiting | Observatory of Patients With Haemophilia B Treated by IdElvion® NCT05086575 | CSL Behring | — |
| Completed | Post-marketing Surveillance (Use Result Surveillance) With Refixia® NCT03875547 | Novo Nordisk A/S | — |
| Enrolling By Invitation | A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN NCT03745924 | Novo Nordisk A/S | — |
| Completed | A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explor NCT03741881 | Novo Nordisk A/S | — |
| Completed | Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophili NCT03276130 | Swedish Orphan Biovitrum | — |
| Enrolling By Invitation | Adverse Event Data Collection From External Registries on Nonacog Beta Pegol NCT03690336 | Novo Nordisk A/S | — |
| Completed | A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children NCT03660774 | Novo Nordisk A/S | — |
| Completed | A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in Franc NCT03655340 | Swedish Orphan Biovitrum | — |
| Completed | A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia NCT03055611 | Swedish Orphan Biovitrum | — |
| Completed | A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B NCT03075670 | Novo Nordisk A/S | Phase 1 |
| Completed | Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) NCT02568202 | Novo Nordisk A/S | — |
| Completed | Thrombin Generation Numerical Models Validation in Haemophilic Case NCT02300519 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives NCT02241694 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B NCT02141074 | Novo Nordisk A/S | Phase 3 |
| Withdrawn | Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects NCT02084810 | Novo Nordisk A/S | Phase 1 |
| Completed | A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care NCT02049099 | Swedish Orphan Biovitrum | — |
| Completed | Project to Update the Study of Congenital Haemophilia in Spain NCT01959555 | Novo Nordisk A/S | — |
| Completed | Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia NCT01988532 | Novo Nordisk A/S | — |
| Completed | A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B NCT01949792 | Novo Nordisk A/S | Phase 1 |
| Completed | Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B NCT01386528 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. NCT01467427 | Novo Nordisk A/S | Phase 3 |
| Completed | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extensio NCT01395810 | Novo Nordisk A/S | Phase 3 |
| Completed | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjec NCT01555749 | Novo Nordisk A/S | Phase 1 |
| Completed | Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries NCT01503567 | Novo Nordisk A/S | — |
| Completed | Survey Evaluating the Psychosocial Effects of Living With Haemophilia NCT01322620 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients NCT01333111 | Novo Nordisk A/S | Phase 3 |
| Completed | Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male NCT01272206 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or NCT01288391 | Novo Nordisk A/S | Phase 1 |
| Completed | Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B NCT01220141 | Novo Nordisk A/S | — |
| Completed | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B NCT01228669 | Novo Nordisk A/S | Phase 1 |
| Completed | Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bl NCT01234545 | Novo Nordisk A/S | — |
| Completed | Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B NCT00956345 | Novo Nordisk A/S | Phase 1 |
| Completed | A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Re NCT00951873 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Facto NCT00922792 | Novo Nordisk A/S | Phase 1 |
| Completed | Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy NCT00638001 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 4 |
| Completed | Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the U NCT00853086 | Novo Nordisk A/S | — |
| Completed | Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds NCT00486278 | Novo Nordisk A/S | Phase 2 |
| Completed | An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Sur NCT02250573 | Bio Products Laboratory | Phase 3 |
| Completed | Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia P NCT01562457 | Novo Nordisk A/S | Phase 1 |
| Completed | A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Y NCT02263469 | Bio Products Laboratory | Phase 3 |
| Completed | Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B i NCT01562587 | Novo Nordisk A/S | Phase 1 |
| Completed | A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Sur NCT02250560 | Bio Products Laboratory | Phase 3 |
| Completed | A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophi NCT02263456 | Bio Products Laboratory | Phase 3 |
| Completed | An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients NCT02231944 | Bio Products Laboratory | Phase 3 |